Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation

Paris (France), May 27, 2020 – 8.45 am CEST - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced the publication of an initiation report by Bryan Garnier & Co, a leading independent European financial services company specialized in research, execution and advisory services.


Bryan Garnier & Co. will now follow Onxeo's share price on the Euronext Paris stock exchange* and values the Company at 1.22 euro per share*.


For more information: ou (Head of Corporate Sales).


* This information does not constitute an offer to sell or subscribe, or the solicitation of an order to buy or subscribe for securities in France, Europe, the US or any other country. Onxeo and Bryan Garnier & Co have agreed on a service for the production and distribution of financial analyses.